# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
RBC Capital analyst Conor McNamara maintains Maravai LifeSciences (NASDAQ:MRVI) with a Outperform and lowers the price targe...
Maravai LifeSciences (NASDAQ:MRVI) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate o...
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and b...
New all-in-one IVT kit can deliver up to 2X more mRNA and up to 85% lower dsRNA compared to other kits on the market through st...
TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ:MRVI) and global provider of life science reagents ...